RS65543B1 - Diazabiciklični supstituisani imidazopirimidini i njihova primena za lečenje poremećaja disanja - Google Patents
Diazabiciklični supstituisani imidazopirimidini i njihova primena za lečenje poremećaja disanjaInfo
- Publication number
- RS65543B1 RS65543B1 RS20240581A RSP20240581A RS65543B1 RS 65543 B1 RS65543 B1 RS 65543B1 RS 20240581 A RS20240581 A RS 20240581A RS P20240581 A RSP20240581 A RS P20240581A RS 65543 B1 RS65543 B1 RS 65543B1
- Authority
- RS
- Serbia
- Prior art keywords
- diazabicyclic
- treatment
- breathing disorders
- substituted imidazopyrimidines
- imidazopyrimidines
- Prior art date
Links
- 150000005237 imidazopyrimidines Chemical class 0.000 title 1
- 230000029058 respiratory gaseous exchange Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17176046 | 2017-06-14 | ||
| EP17193252 | 2017-09-26 | ||
| PCT/EP2018/064977 WO2018228907A1 (de) | 2017-06-14 | 2018-06-07 | Diazabicyclisch substituierte imidazopyrimidine und ihre verwendung zur behandlung von atemstörungen |
| EP18728646.3A EP3638675B1 (de) | 2017-06-14 | 2018-06-07 | Diazabicyclisch substituierte imidazopyrimidine und ihre verwendung zur behandlung von atemstörungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS65543B1 true RS65543B1 (sr) | 2024-06-28 |
Family
ID=62492660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20240581A RS65543B1 (sr) | 2017-06-14 | 2018-06-07 | Diazabiciklični supstituisani imidazopirimidini i njihova primena za lečenje poremećaja disanja |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US11098063B2 (pt-PT) |
| EP (1) | EP3638675B1 (pt-PT) |
| JP (2) | JP6896113B2 (pt-PT) |
| KR (1) | KR102364134B1 (pt-PT) |
| CN (4) | CN115554299A (pt-PT) |
| AR (1) | AR112099A1 (pt-PT) |
| AU (1) | AU2018283331B2 (pt-PT) |
| BR (1) | BR112019026450A2 (pt-PT) |
| CA (1) | CA3066942A1 (pt-PT) |
| CL (1) | CL2019003650A1 (pt-PT) |
| CO (1) | CO2019014047A2 (pt-PT) |
| CR (1) | CR20190563A (pt-PT) |
| CU (1) | CU24603B1 (pt-PT) |
| DO (1) | DOP2019000308A (pt-PT) |
| EA (1) | EA202090043A1 (pt-PT) |
| EC (1) | ECSP19088492A (pt-PT) |
| GE (1) | GEP20227366B (pt-PT) |
| IL (1) | IL271117B (pt-PT) |
| JO (1) | JOP20190284A1 (pt-PT) |
| MA (1) | MA49368A (pt-PT) |
| MX (2) | MX2019014983A (pt-PT) |
| NI (1) | NI201900126A (pt-PT) |
| PE (1) | PE20200016A1 (pt-PT) |
| PH (1) | PH12019502828A1 (pt-PT) |
| RS (1) | RS65543B1 (pt-PT) |
| SG (1) | SG11201911508XA (pt-PT) |
| TW (1) | TWI801388B (pt-PT) |
| UA (1) | UA125186C2 (pt-PT) |
| UY (1) | UY37773A (pt-PT) |
| WO (1) | WO2018228907A1 (pt-PT) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018011783A2 (pt) | 2015-12-10 | 2018-12-04 | Bayer Pharma Aktiengesellschaft | derivados de 2-fenil-3-(piperazinometil)imidazo[1,2-a]piridina, como bloqueadores dos canais de task-1 e task-2 para o tratamento de transtornos respiratórios relacionados ao sono |
| JOP20190284A1 (ar) * | 2017-06-14 | 2019-12-11 | Bayer Pharma AG | مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس |
| WO2018227427A1 (en) | 2017-06-14 | 2018-12-20 | Bayer Aktiengesellschaft | Substituted bridged diazepane derivatives and use thereof |
| EP3965766A1 (en) * | 2019-05-09 | 2022-03-16 | Bayer Aktiengesellschaft | Combination of an ?2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea |
| CA3139298A1 (en) | 2019-05-09 | 2020-11-12 | Bayer Aktiengesellschaft | Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea |
| MX2022005414A (es) | 2019-11-06 | 2022-05-26 | Bayer Ag | Inhibidores de adrenoreceptor adrac2. |
| CN116057057A (zh) | 2020-07-06 | 2023-05-02 | 拜耳公司 | 用于治疗睡眠呼吸暂停的α2-肾上腺素受体亚型C(α-2C)拮抗剂与TASK1/3通道阻断剂的结合物 |
| GB202101734D0 (en) * | 2021-02-08 | 2021-03-24 | Cerevance Inc | Novel Compounds |
| WO2023118102A1 (en) | 2021-12-22 | 2023-06-29 | Bayer Aktiengesellschaft | Combination of a task1/3 channel blocker with a muscarinic receptor antagonist for the treatment of sleep apnea |
| AU2022422284A1 (en) | 2021-12-22 | 2024-07-04 | Bayer Aktiengesellschaft | Combination of a task1/3 channel blocker with a norepinephrine reuptake inhibitor for the treatment of sleep apnea |
| WO2023118122A1 (en) | 2021-12-22 | 2023-06-29 | Bayer Aktiengesellschaft | Combination of a task1/3 channel blocker with a p2x3 receptor antagonist for the treatment of sleep apnea |
| WO2023131640A1 (en) | 2022-01-07 | 2023-07-13 | Bayer Aktiengesellschaft | α2-ADRENOCEPTOR SUBTYPE C ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA |
| WO2023131638A1 (en) | 2022-01-07 | 2023-07-13 | Bayer Aktiengesellschaft | 2,3-dihydrobenzo [b][1, 4]dioxin-2-ylmethyl)piperazin-1-yl derivates for the treatment of sleep apnea |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| MY125533A (en) * | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| WO2002002557A2 (en) | 2000-06-30 | 2002-01-10 | Neurogen Corporation | 2-phenylimidazo[1,2-a]pyridine derivatives: a new class of gaba brain receptor ligands |
| GB0017256D0 (en) | 2000-07-13 | 2000-08-30 | Merck Sharp & Dohme | Therapeutic agents |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| SE0100568D0 (sv) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | Compounds |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| DE10247269A1 (de) | 2002-10-10 | 2004-04-22 | Grünenthal GmbH | Substituierte C-Imidazo[1,2-a]pyridin-3-yl-methylamine |
| US7855194B2 (en) * | 2006-03-27 | 2010-12-21 | Hoffmann-La Roche Inc. | Pyrimidine, quinazoline, pteridine and triazine derivatives |
| AU2007245891B2 (en) * | 2006-04-27 | 2012-10-18 | Sanofi-Aventis Deutschland Gmbh | Inhibitors of the TASK-1 and TASK-3 ion channel |
| EP2049110B1 (en) * | 2006-07-14 | 2014-08-20 | Merck Sharp & Dohme Corp. | Bridged diazepan orexin receptor antagonists |
| EP1974729A1 (en) | 2007-03-28 | 2008-10-01 | Santhera Pharmaceuticals (Schweiz) AG | Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists |
| EP2300470A2 (en) | 2008-05-19 | 2011-03-30 | Sepracor Inc. | Imidazo[1,2-a]pyridine compounds as gaba-a receptor modulators |
| WO2011115804A1 (en) | 2010-03-17 | 2011-09-22 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| SG10201502109VA (en) | 2010-03-18 | 2015-05-28 | Pasteur Institut Korea | Anti-infective compounds |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| CN103097387B (zh) | 2010-07-09 | 2016-11-02 | 拜耳知识产权有限责任公司 | 环稠合的嘧啶和三嗪以及其用于治疗和/或预防心血管疾病的用途 |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| CN103298468A (zh) | 2011-02-01 | 2013-09-11 | 协和发酵麒麟株式会社 | 稠环杂环衍生物 |
| WO2012130322A1 (en) | 2011-03-31 | 2012-10-04 | Elara Pharmaceuticals Gmbh | Imidazo [1,2-a]pyridine compounds for use in therapy |
| KR102104125B1 (ko) | 2011-04-21 | 2020-05-29 | 재단법인 한국파스퇴르연구소 | 소염 화합물 |
| EA023648B1 (ru) | 2011-09-12 | 2016-06-30 | Санофи | ИНДАНИЛЗАМЕЩЕННЫЕ 4,5,6,7-ТЕТРАГИДРО-1H-ПИРАЗОЛО[4,3-с]ПИРИДИНЫ, ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННОГО СРЕДСТВА И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ |
| ES2559450T3 (es) | 2011-09-16 | 2016-02-12 | Sanofi | 4,5,6,7-Tetrahidro-1H-pirazolo[4,3-c]piridinas sustituidas, su uso como medicamento, y preparaciones farmacéuticas que las comprenden |
| WO2013037914A1 (en) * | 2011-09-16 | 2013-03-21 | Sanofi | Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them |
| KR102017362B1 (ko) | 2012-02-03 | 2019-09-02 | 사노피 | 축합 피롤디카복사미드 및 약제로서의 그의 용도 |
| JP2016527184A (ja) * | 2013-05-24 | 2016-09-08 | イオメット ファーマ リミテッド | Ｓｌｃ２ａ輸送体阻害剤 |
| DK3122750T3 (da) | 2014-03-26 | 2019-11-04 | Hoffmann La Roche | Bicykliske forbindelser som autotaxin (ATX)- og lysofosfatidsyre (LPA)-produktionshæmmere |
| JP2018012645A (ja) | 2014-11-26 | 2018-01-25 | 持田製薬株式会社 | 新規ジアザビシクロ誘導体 |
| US10000499B2 (en) | 2014-11-26 | 2018-06-19 | Merck Sharp & Dohme Corp. | Methyl diazepane orexin receptor antagonists |
| TWI585785B (zh) * | 2014-11-26 | 2017-06-01 | Murata Manufacturing Co | Electronic parts manufacturing methods, electronic components and electronic devices |
| US9994570B2 (en) | 2014-11-26 | 2018-06-12 | Merck Sharp & Dohme Corp. | Bridged diazepane orexin receptor antagonists |
| JP2018016544A (ja) | 2014-12-03 | 2018-02-01 | 持田製薬株式会社 | 新規ジアザビシクロ［２．２．２］オクタン誘導体 |
| BR112018006024A2 (pt) | 2015-09-24 | 2020-05-12 | F. Hoffmann-La Roche Ag | Compostos bicíclicos como inibidores de atx |
| BR112018011783A2 (pt) | 2015-12-10 | 2018-12-04 | Bayer Pharma Aktiengesellschaft | derivados de 2-fenil-3-(piperazinometil)imidazo[1,2-a]piridina, como bloqueadores dos canais de task-1 e task-2 para o tratamento de transtornos respiratórios relacionados ao sono |
| JP2018538296A (ja) * | 2015-12-10 | 2018-12-27 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換ペルヒドロピロロ［３，４−ｃ］ピロール誘導体およびその使用 |
| JOP20190005A1 (ar) | 2016-07-20 | 2019-01-20 | Bayer Ag | مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها |
| JOP20190148A1 (ar) | 2016-12-21 | 2019-06-18 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية |
| JOP20190141A1 (ar) | 2016-12-21 | 2019-06-12 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي |
| JOP20190284A1 (ar) * | 2017-06-14 | 2019-12-11 | Bayer Pharma AG | مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس |
| WO2018227427A1 (en) | 2017-06-14 | 2018-12-20 | Bayer Aktiengesellschaft | Substituted bridged diazepane derivatives and use thereof |
| EP3965766A1 (en) | 2019-05-09 | 2022-03-16 | Bayer Aktiengesellschaft | Combination of an ?2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea |
| CA3139298A1 (en) | 2019-05-09 | 2020-11-12 | Bayer Aktiengesellschaft | Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea |
-
2017
- 2017-06-16 JO JOP/2019/0284A patent/JOP20190284A1/ar unknown
-
2018
- 2018-06-07 CN CN202211199746.0A patent/CN115554299A/zh active Pending
- 2018-06-07 JP JP2019569416A patent/JP6896113B2/ja active Active
- 2018-06-07 UA UAA202000222A patent/UA125186C2/uk unknown
- 2018-06-07 EA EA202090043A patent/EA202090043A1/ru unknown
- 2018-06-07 CN CN202211200547.7A patent/CN115554300A/zh active Pending
- 2018-06-07 AU AU2018283331A patent/AU2018283331B2/en active Active
- 2018-06-07 KR KR1020207000676A patent/KR102364134B1/ko active IP Right Grant
- 2018-06-07 US US16/622,233 patent/US11098063B2/en active Active
- 2018-06-07 BR BR112019026450-7A patent/BR112019026450A2/pt unknown
- 2018-06-07 GE GEAP201815256A patent/GEP20227366B/en unknown
- 2018-06-07 SG SG11201911508XA patent/SG11201911508XA/en unknown
- 2018-06-07 CN CN201880039548.3A patent/CN110719911B/zh active Active
- 2018-06-07 PE PE2019002541A patent/PE20200016A1/es unknown
- 2018-06-07 RS RS20240581A patent/RS65543B1/sr unknown
- 2018-06-07 MX MX2019014983A patent/MX2019014983A/es unknown
- 2018-06-07 MA MA049368A patent/MA49368A/fr unknown
- 2018-06-07 CN CN202211200627.2A patent/CN115583959B/zh active Active
- 2018-06-07 CR CR20190563A patent/CR20190563A/es unknown
- 2018-06-07 CU CU2019000101A patent/CU24603B1/es unknown
- 2018-06-07 CA CA3066942A patent/CA3066942A1/en active Pending
- 2018-06-07 WO PCT/EP2018/064977 patent/WO2018228907A1/de unknown
- 2018-06-07 EP EP18728646.3A patent/EP3638675B1/de active Active
- 2018-06-12 TW TW107120117A patent/TWI801388B/zh active
- 2018-06-13 AR ARP180101619A patent/AR112099A1/es unknown
- 2018-06-14 UY UY0001037773A patent/UY37773A/es unknown
-
2019
- 2019-12-02 IL IL271117A patent/IL271117B/en unknown
- 2019-12-11 MX MX2022012716A patent/MX2022012716A/es unknown
- 2019-12-12 NI NI201900126A patent/NI201900126A/es unknown
- 2019-12-12 CO CONC2019/0014047A patent/CO2019014047A2/es unknown
- 2019-12-12 CL CL2019003650A patent/CL2019003650A1/es unknown
- 2019-12-12 EC ECSENADI201988492A patent/ECSP19088492A/es unknown
- 2019-12-13 DO DO2019000308A patent/DOP2019000308A/es unknown
- 2019-12-13 PH PH12019502828A patent/PH12019502828A1/en unknown
-
2021
- 2021-06-04 JP JP2021094338A patent/JP2021127346A/ja active Pending
- 2021-07-16 US US17/305,927 patent/US20220017540A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271117B (en) | Diazabicyclic mutated imidazopyrimidines and their use in the treatment of respiratory disorders | |
| IL279752B (en) | Polycyclic compounds and their use in the treatment of immune disorders | |
| IL271085B2 (en) | Bacteria to treat disorders | |
| PT3215511T (pt) | Pirazolo(1,5-a)pirimidinas substituídas e a sua utilização no tratamento de distúrbios médicos | |
| ZA201908165B (en) | Compounds for the prevention and treatment of diseases and the use thereof | |
| HK1257321A1 (zh) | 用於治療腦組織的組織摧毀術治療系統和方法 | |
| IL290754A (en) | Use of pyridofidine to treat anxiety and depression | |
| EP3344632A4 (en) | Heterocyclic pyrimidine compounds and their use in the treatment of medical disorders | |
| IL265635A (en) | Combined treatments including imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders | |
| GB2542155B (en) | Use of cannabidiol in the treatment of mental disorders | |
| GB201617064D0 (en) | Compounds and their therapeutic use | |
| IL281585B (en) | Selenogalactoside compounds for the prevention and treatment of galectin-related diseases and their use | |
| GB201715194D0 (en) | Compounds and their therapeutic use | |
| HK1257588A1 (zh) | 預防和治療肺纖維化的藥物及其用途 | |
| IL272097A (en) | Compounds for the prevention and treatment of medical disorders and their uses | |
| GB201519557D0 (en) | Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions | |
| EP3723742C0 (fr) | Utilisation de la fluoroethylnormemantine pour la prevention et le traitement de l'anxiete | |
| RS63321B1 (sr) | Formulacije za primenu u lečenju endometrioze i poremećaja koji su sa njom u vezi | |
| IL277805A (en) | Use of gaboksadol in the treatment of substance use disorders | |
| IL275349A (en) | Use of hM4Di in the treatment of seizure disorders | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| IL274838A (en) | Use of MIR101 or MIR128 in the treatment of seizure disorders | |
| ZA201806894B (en) | (+)-azasetron for use in the treatment of ear disorders | |
| GB201820455D0 (en) | Compounds and their use for the treatment of alpha1-antitryspin deficiency |